Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.

The US FDA approved Rexulti as the first drug for agitation in Alzheimer’s disease, a multibillion-dollar market where Lundbeck estimates it could bring in $1bn in annual sales.

Califf tweaks his misinformation stump speech, FDA adds to the Twitter COVID vaccine confusion with a tweet to Elon Musk, generic firms are schooled on the difference between a teleconference and a video conference, and other observations from Pink Sheet reporters’ notebooks.

AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.